GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CELLDEX THERAPEUTICS INC

Explicit Guidance:

• BLA Submission: Expectation to file a Biologics License Application (BLA) in 2027, contingent upon the full 52-week clinical data set.
• Data Readouts:
  • Q1 AI 2027: Presentation of full 24-week efficacy and secondary endpoints for the Barzavolumab program.
  • End of Year 2024: Release of data from the Phase 3 Atopic Dermatitis (AD) study.
  • Next Few Months: Additional guidance expected regarding the ongoing Phase 3 Sindutim (SIndu) trial enrollment.
• Financial Runway: Cash position of $650 million as of Q3 is sufficient to fund operations through 2028, aligning with the initial product launch timeline.
• Payer Strategy: Intent to pursue a "premium value-based price" for Barzavolumab reflecting the value of complete symptom clearance, with preliminary payer discussions indicating receptiveness.

Business-Segment Outlook:

• Barzavolumab (CSU): Projected to target two key populations: first-line therapy for severe disease/angioedema (estimated >25% of first-line candidates) and second-line therapy for patients refractory to Omalizumab or Dupilumab. Anticipated to follow a pattern seen in other biologic categories where second-line therapy usage eventually eclipses first-line therapy.
• Sindutim (SIndu): Barzavolumab is positioned to become the second approved therapy in a market with global prevalence in the "tens of millions" and high unmet need; Phase 3 enrollment is ongoing and proceeding well.
• Atopic Dermatitis (AD): Phase 3 study enrolling moderately severe patients (mix of treatment-naive and biologic-experienced); success metric is defined as being "at least as good as, if not better than," currently existing therapies.
• Cdx622 (Pipeline): A complementary antibody targeting soluble stem cell factor (SCF) and TSLP pathways currently in proof-of-mechanism studies for asthma; exploring potential future indications including food allergy.
• Commercial Infrastructure: Building out Market Analytics, Brand, and Payer teams in anticipation of Payer Exchange engagements in the first half of 2027; MSL team expansion underway to disseminate Phase 3 data.

Market and Competitive Outlook:

• CSU Market Dynamics: Current market penetration is low (only 30% of estimated prevalence diagnosed; <20% of diagnosed eligible patients receive advanced therapy); company expects market growth similar to the IL-23 therapy evolution in psoriasis where "complete clearance" shifted treatment paradigms.
• Competitive Differentiation: Barzavolumab targets unique value propositions: complete response in the majority of patients, rapid/deepening efficacy, ability to treat severe first-line cases with angioedema, and a dosing regimen requiring only 7 days/year (Q8 dosing), which is unique among approved therapies.
• Unmet Need: Approximately 60-70% of patients on current second-line biologics (Omalizumab/Dupilumab) remain uncontrolled, driving demand for superior efficacy; high attrition rates (~50% at one year) for current biologics present significant opportunity for Barzavolumab.

Macro / Industry Outlook:

• Treatment Paradigm Shift: Industry trend moving toward therapies that deliver "complete clearance" rather than partial symptom improvement, similar to the evolution in psoriasis and the shift of second-line biologics overtaking first-line.
• Regulatory Expectations: Anticipation of a label indication for omalizumab-refractory patients, though specific wording is pending FDA negotiation.
• Safety Profile Expectations: Company expects a safety label similar to other biologics, with language in the "Warnings and Precautions" section regarding hypersensitivity/anaphylaxis, based on a conservative grading scale used in Phase 3.

Strategic Initiatives:

• Capacity/Workforce Expansion: Active expansion of the Medical Science Liaison (MSL) team and development of dedicated Market Analytics, Brand, and Payer exchange teams to prepare for 2027 launch.
• Milestone-Driven Growth: Commercial build-out is strictly tied to data milestones (Phase 3 results) and regulatory progress (BLA submission in 2027).
• Portfolio Synergy: Strategy to lead the "mass cell science" space by deploying complementary mechanisms: Barzavolumab (anti-KIT) and Cdx622 (anti-SCF/TSLP) to target immunoinflammatory diseases via multiple pathways.

Risks and Headwinds to Outlook:

• Data Timing Risks: Completion of off-therapy durability data (prolonged response) for Phase 3 is delayed compared to Phase 2, requiring a wait for the long-term extension study results.
• Safety Ambiguities: While anaphylaxis cases were adjudicated as more frequent in the placebo arm in Phase 3, the presence of any adjudicated cases requires careful label negotiation regarding anaphylaxis warnings.
• Regulatory Uncertainty: Specific labeling for the omalizumab-refractory subgroup is not finalized and depends on FDA negotiation.
• Pipeline Execution: Cdx622 is still in proof-of-mechanism stages (asthma); success in this early stage is required before confirming broader indications like food allergy.
• Adoption Dynamics: While second-line therapy growth is anticipated, the rate at which "second-line therapy eclipses first-line" depends on payer acceptance of value-based pricing and clinical adoption of the complete response metric.

Management Tone on the Future:

• Confidence: High confidence in the "unique profile" and "best-in-disease" efficacy of Barzavolumab, described as "practice-changing" and "compelling."
• Strategic Focus: Tone is disciplined and data-driven, emphasizing the ability to target large unmet needs and achieve "complete response" where competitors fail.
• Timeline Certainty: Firm guidance on 2027 BLA submission, with specific visibility on data readouts for 2024 (AD) and Q1 2027 (CSU 24-week data).
• Value Perception: Strong belief that payers will recognize the economic differentiation of "complete response" and support a premium price, drawing parallels to the psoriasis market.

Miscellaneous:

• Phase 2 Analogy: 41% of Phase 2 patients maintained complete response 7 months after stopping therapy, a durability metric expected but not yet fully realized in the Phase 3 dataset.
• Dosing Flexibility: Offering both Q4 (monthly) and Q8 (every 8 weeks) options to accommodate varying physician practice styles and patient preferences.
• Off-Label Considerations: Management declined to comment on specific off-label uptake for Sindutim (SIndu) regarding Barzavolumab's future use, citing regulatory constraints.